share_log

Daxor Expands Its BVA-100 Blood Volume Diagnostic to Two New Hospital Systems Adding to Sales Momentum

Daxor Expands Its BVA-100 Blood Volume Diagnostic to Two New Hospital Systems Adding to Sales Momentum

Daxor将其BVA-100血容量诊断扩展到两个新的医院系统,增加销售动力
GlobeNewswire ·  12/18 08:00

Healthcare Providers Embrace Blood Volume Analysis (BVA) in Nephrology and Heart Failure Outpatient Care

医疗提供者在肾脏病和心力衰竭门诊护理中采纳血容量分析(BVA)

Oak Ridge, TN, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces expansion of its ezBVA Lab service to two new health systems. Daxor's ezBVA Lab provides cost-effective blood volume analysis, offering comprehensive sample processing with minimal initial investment. The service has broad reimbursement coverage across hospitals and ambulatory care settings.

美国田纳西州奥克里奇, 2024年12月18日 (全球资讯网) -- Daxor公司 (纳斯达克: DXR),血容量测量技术的全球领导者,今天宣布将其ezBVA实验室服务扩展到两个新的医疗系统。Daxor的ezBVA实验室提供具有成本效益的血容量分析,提供全面的样本处理,初始投资最低。该服务在医院和门诊护理环境中具有广泛的报销覆盖。

New wins include:

新获得的胜利包括:

  • A major Arizona-based multi-campus medical center has adopted our BVA technology for outpatient nephrology care with further departments to follow in 2025.
  • A regional health network serving communities across Southwest Iowa, Nebraska, Minnesota, and North Dakota has agreed to implement BVA for heart failure outpatient management.
  • 一家总部位于亚利桑那州的大型多校区医疗中心已采用我们的BVA技术开展门诊肾脏病护理,预计在2025年将进一步扩展至其他科室。
  • 一个区域型卫生网络为服务于西南爱荷华州、内布拉斯加州、明尼苏达州和北达科他州的社区已同意实施BVA以管理心力衰竭的门诊护理。

"Our BVA platform is a critical diagnostic tool that redefines outpatient care by providing real-time insights into a patient's volume status. By enabling early detection of fluid imbalances and cardiovascular risks, BVA empowers clinicians to intervene proactively, potentially preventing costly hospitalizations, reducing emergency interventions, and personalizing patient treatment strategies," said John Jefferies, Daxor's Chief Medical Officer.

"我们的BVA平台是一个关键的诊断工具,重新定义了门诊护理,通过提供患者体积状态的实时洞察来实现。有助于提早发现液体失衡和心血管风险,BVA使临床医生能够主动干预,从而可能防止昂贵的医院入住,减少急救干预,并个性化患者治疗策略," Daxor首席医疗官约翰·杰弗里斯说。

"The continued sales growth that the company is experiencing has positioned us for our best quarter ever in terms of revenue and year-over-year growth reflecting the focus of our commercialization team and the increasing customer engagement driven by our clinical education team," said Michael Feldschuh, Daxor's CEO and President.

"公司目前经历的持续销售增长使我们在营业收入和同比增长方面有望实现历来最佳季度,这反映了我们商业化团队的重点和我们临床教育团队推动的客户参与日益增加," Daxor首席执行官兼总裁迈克尔·费尔施胡说。

About Daxor Corporation

关于Daxor公司

Daxor Corporation (Nasdaq: DXR), is the global leader in blood volume measurement technology focused on blood volume testing innovation. We developed and market the BVA-100 (Blood Volume Analyzer), the only diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000+ tests have been performed at leading hospital centers across the U.S., enhancing hospital performance metrics in a broad range of surgical and medical conditions, including significantly reducing mortality and readmissions in heart failure and critical care. Daxor has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the U.S. Department of Defense. Daxor's mission is to advance healthcare by enabling optimal fluid management with blood volume analysis. Daxor's vision is optimal blood volume for all. For more information, please visit our website at Daxor.com. Sign up to receive news on Daxor's innovative technology HERE.

Daxor Corporation (Nasdaq: DXR), is the global leader in blood volume measurement technology focused on blood volume testing innovation. We developed and market the BVA-100 (Blood Volume Analyzer), the only diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000+ tests have been performed at leading hospital centers across the U.S., enhancing hospital performance metrics in a broad range of surgical and medical conditions, including significantly reducing mortality and readmissions in heart failure and critical care. Daxor has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the U.S. Department of Defense. Daxor's mission is to advance healthcare by enabling optimal fluid management with blood volume analysis. Daxor's vision is optimal blood volume for all. For more information, please visit our website at Daxor.com. Sign up to receive news on Daxor's innovative technology 在这里.

Forward-Looking Statements

前瞻性声明

Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

本公告中的某些声明可能包括1995年《私人证券诉讼改革法案》定义的前瞻性声明,包括但不限于关于招聘销售人员及扩展我们分销渠道影响的声明。前瞻性声明是关于未来事件的预测、项目和其他声明,这些声明基于当前的期望和假设,因此受到风险和不确定性的影响。许多因素可能导致实际未来事件与本公告中的前瞻性声明存在重大差异,包括但不限于与我们的上市后临床数据收集活动相关的风险、我们的产品对患者的益处、我们对产品开发和商业化努力的期望、我们增加市场和医生接受我们产品能力的能力、潜在的竞争产品提供、知识产权保护、FDA监管措施、我们整合收购业务的能力、我们对预期协同效应及从收购业务中获得的利益的期望,以及在我们向SEC提交的文件中描述的其他风险和不确定性。前瞻性声明仅在作出时有效。Daxor不承担任何义务公开更新或修订任何前瞻性声明,无论是由于新信息、未来事件还是其他原因。

Investor Relations Contact:
Bret Shapiro
Sr. Managing Partner, CORE IR
1-516-222-2560
brets@coreir.com

投资者关系联系:
布雷特·夏皮罗
高级管理合伙人,核心投资关系
1-516-222-2560
brets@coreir.com


声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发